Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers

ABSTRACT

The present invention is directed to nanoparticulate compositions comprising a poorly soluble drug and at least one copolymer of vinyl pyrrolidone and vinyl acetate as a surface stabilizer adsorbed to the surface of the drug. Also encompassed by the invention are pharmaceutical compositions comprising a nanoparticulate composition of the invention, methods of making and using such nanoparticulate and pharmaceutical compositions.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application is a Continuation of U.S. application Ser. No.09/715,117, filed Nov. 20, 2000 now abandoned, incorporated herein byreference in its entirety. This application is also aContinuation-in-part of U.S. application Ser. No. 10/075,443, filed Feb.15, 2002 now U.S. Pat. No. 6,592,903, incorporated herein by referencein its entirety, which is a Continuation of U.S. application Ser. No.09/666,539, filed Sep. 21, 2000, now U.S. Pat. No. 6,375,986, issuedApr. 23, 2002, incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention is directed to nanoparticulate formulations of adrug having at least one copolymer of vinyl pyrrolidone and vinylacetate adsorbed on the surface of the drug as a surface stabilizer, andmethods of making and using such compositions.

BACKGROUND OF THE INVENTION

Nanoparticulate compositions, first described in U.S. Pat. No. 5,145,684(“the '684 patent”), are particles consisting of a poorly solubletherapeutic or diagnostic agent having adsorbed onto the surface thereofa non-crosslinked surface stabilizer. The '684 patent describes the useof a variety of surface stabilizers for nanoparticulate compositions.The use of a copolymer of vinyl pyrrolidone and vinyl acetate as asurface stabilizer for nanoparticulate compositions, or any othercomponent of such compositions, is not described by the '684 patent.

The '684 patent describes a method of screening drugs to identify usefulsurface stabilizers that enable the production of a nanoparticulatecomposition. Not all surface stabilizers will function to produce astable, non-agglomerated nanoparticulate composition for all drugs.Moreover, known surface stabilizers may be unable to produce a stable,non-agglomerated nanoparticulate composition for certain drugs. Thus,there is a need in the art to identify new surface stabilizers useful inmaking nanoparticulate compositions. Additionally, such new surfacestabilizers may have superior properties over prior known surfacestabilizers.

There is a need in the art for new surface stabilizers fornanoparticulate compositions of poorly soluble drugs. In addition, thereis a need in the art for surface stabilizers useful in preparingnanoparticulate compositions of drugs, in which prior known surfacestabilizers are ineffective. The present invention satisfies theseneeds.

SUMMARY OF THE INVENTION

The present invention is directed to nanoparticulate compositionscomprising a poorly soluble drug and at least one copolymer of vinylpyrrolidone and vinyl acetate as a surface stabilizer adsorbed to thesurface of the drug.

Another aspect of the invention is directed to pharmaceuticalcompositions comprising a nanoparticulate composition of the invention.The pharmaceutical composition preferably comprises a poorly solubledrug, at least one copolymer of vinyl pyrrolidone and vinyl acetate as asurface stabilizer adsorbed to the surface of the drug, and apharmaceutically acceptable carrier, as well as any desired excipients.

This invention further discloses a method of making a nanoparticulatecomposition having at least one copolymer of vinyl pyrrolidone and vinylacetate as a surface stabilizer adsorbed on the surface of the drug.Such a method comprises contacting a poorly soluble nanoparticulate drugwith at least one copolymer of vinyl pyrrolidone and vinyl acetate as asurface stabilizer for a time and under conditions sufficient to providea nanoparticle/copolymer composition. The copolymer surface stabilizerscan be contacted with the drug either before, during, or after sizereduction of the drug.

The present invention is further directed to a method of treatmentcomprising administering to a mammal in need a therapeutically effectiveamount of a nanoparticulate drug/copolymer composition according to theinvention.

Both the foregoing general description and the following detaileddescription are exemplary and explanatory and are intended to providefurther explanation of the invention as claimed. Other objects,advantages, and novel features will be readily apparent to those skilledin the art from the following detailed description of the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed to a composition comprisingnanoparticulate drug having at least one copolymer of vinyl pyrrolidoneand vinyl acetate as a surface stabilizer adsorbed on the surfacethereof, and methods of making and using such nanoparticulatecompositions.

A. Compositions

The compositions of the invention comprise nanoparticulate drug and atleast one copolymer of vinyl pyrrolidone and vinyl acetate as a surfacestabilizer adsorbed to the surface of the drug. Surface stabilizersuseful herein physically adhere to the surface of the nanoparticulatedrug, but do not chemically react with the drug or itself. Individuallyadsorbed molecules of the surface stabilizer are essentially free ofintermolecular cross-linkages.

The present invention also includes nanoparticulate compositions havingat least one copolymer of vinyl pyrrolidone and vinyl acetate as asurface stabilizer adsorbed on the surface thereof, formulated intocompositions together with one or more non-toxic physiologicallyacceptable carriers, adjuvants, or vehicles, collectively referred to ascarriers. The compositions can be formulated for parenteral injection,oral administration in solid or liquid form, rectal or topicaladministration, and the like.

1. Drug Particles

The nanoparticles of the invention comprise a therapeutic or diagnosticagent, collectively referred to as a “drug.” A therapeutic agent can bea pharmaceutical agent, including biologics such as proteins, peptides,and nucleotides, or a diagnostic agent, such as a contrast agent,including x-ray contrast agents. The drug exists either as a discrete,crystalline phase, or as an amorphous phase. The crystalline phasediffers from a non-crystalline or amorphous phase which results fromprecipitation techniques, such as those described in EP Patent No.275,796.

The invention can be practiced with a wide variety of drugs. The drug ispreferably present in an essentially pure form, is poorly soluble, andis dispersible in at least one liquid medium. By “poorly soluble” it ismeant that the drug has a solubility in the liquid dispersion medium ofless than about 10 mg/mL, and preferably of less than about 1 mg/mL.

The drug can be selected from a variety of known classes of drugs,including, for example, proteins, peptides, nucleotides, anti-obesitydrugs, nutriceuticals, corticosteroids, elastase inhibitors, analgesics,antifungals, oncology therapies, anti-emetics, analgesics,cardiovascular agents, anti-inflammatory agents, anthelmintics,anti-arrhythmic agents, antibiotics (including penicillins),anticoagulants, antidepressants, antidiabetic agents, antiepileptics,antihistamines, antihypertensive agents, antimuscarinic agents,antimycobacterial agents, antineoplastic agents, immunosuppressants,antithyroid agents, antiviral agents, anxiolytic sedatives (hypnoticsand neuroleptics), astringents, beta-adrenoceptor blocking agents, bloodproducts and substitutes, cardiac inotropic agents, contrast media,corticosteroids, cough suppressants (expectorants and mucolytics),diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics(antiparkinsonian agents), haemostatics, immuriological agents, lipidregulating agents, muscle relaxants, parasympathomimetics, parathyroidcalcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals,sex hormones (including steroids), anti-allergic agents, stimulants andanoretics, sympathomimetics, thyroid agents, vasodilators and xanthines.

The drugs are commercially available and/or can be prepared bytechniques known in the art.

2. Copolymer Surface Stabilizers

Commercially available copolymers of vinyl pyrrolidone and vinyl acetateare Plasdone® S630 (ISP) and Kollidon® VA 64 (BASF), which contain vinylpyrrolidone and vinyl acetate in a 60:40 ratio. Other copolymers ofvinyl pyrrolidone and vinyl acetate can also be used in the invention.Preferably, the copolymer contains at least 40% vinyl pyrrolidone,although smaller amounts of vinyl pyrrolidone can also be utilized.Other useful copolymers contain vinyl pyrrolidone and vinyl acetate inratios of, for example, 90:10, 80:20, 70:30, and 50:50. The amount ofvinyl pyrrolidone can range from about 40% up to about 99.9%, and theamount of vinyl acetate can range from about 0.1% up to about 60%.

Two or more surface stabilizers can be used in combination.

3. Auxiliary Surface Stabilizers

The compositions of the invention can also include one or more auxiliarysurface stabilizers in addition to the at least one copolymer of vinylpyrrolidone and vinyl acetate. Suitable auxiliary surface stabilizerscan preferably be selected from known organic and inorganicpharmaceutical excipients. Such excipients include various polymers, lowmolecular weight oligomers, natural products, and surfactants. Preferredsurface stabilizers include nonionic and ionic surfactants. Two or moresurface auxiliary stabilizers can be used in combination.

Representative examples of auxiliary surface stabilizers include cetylpyridinium chloride, gelatin, casein, lecithin (phosphatides), dextran,glycerol, gum acacia, cholesterol, tragacanth, stearic acid,benzalkonium chloride, calcium stearate, glycerol monostearate,cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters,polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitanfatty acid esters (e.g., the commercially available Tweens® such ase.g., Tween 20® and Tween 80® (ICI Specialty Chemicals)); polyethyleneglycols (e.g., Carbowaxes 3350® and 1450®, and Carbopol 934® (UnionCarbide)), dodecyl trimethyl ammonium bromide, polyoxyethylenestearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate,carboxymethylcellulose calcium, hydroxypropyl celluloses (e.g., HPC,HPC-SL, and HPC-L), hydroxypropyl methylcellulose (HPMC),carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose,hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose,magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA),polyvinylpyrrolidone (PVP), 4-(1,1,3,3-tetramethylbutyl)-phenol polymerwith ethylene oxide and formaldehyde (also known as tyloxapol,superione, and triton), poloxamers (e.g., Pluronics F68® and F108®,which are block copolymers of ethylene oxide and propylene oxide);poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, whichis a tetrafunctional block copolymer derived from sequential addition ofpropylene oxide and ethylene oxide to ethylenediamine (BASF WyandotteCorporation, Parsippany, N.J.)); a charged phospholipid such asdimyristoyl phophatidyl glycerol, dioctylsulfosuccinate (DOSS); Tetronic1508® (T-1508) (BASF Wyandotte Corporation), dialkylesters of sodiumsulfosuccinic acid (e.g., Aerosol OT®, which is a dioctyl ester ofsodium sulfosuccinic acid (Cytec Industries, West Paterson, N.J.));Duponol P®, which is a sodium lauryl sulfate (DuPont); Triton X-200®,which is an alkyl aryl polyether sulfonate (Union Carbide); CrodestasF-110®, which is a mixture of sucrose stearate and sucrose distearate(Croda Inc.); p-isononylphenoxypoly-(glycidol), also known as Olin-IOG®or Surfactant 10-G® (Olin Chemicals, Stamford, Conn.); Crodestas SL-40®(Croda, Inc.); decanoyl-N-methylglucamide; n-decyl β-D-glucopyranoside;n-decyl β-D-maltopyranoside; n-dodecyl β-D-glucopyranoside; n-dodecylβ-D-maltoside; heptanoyl-N-methylglucamide;n-heptyl-β-D-glucopyranoside; n-heptyl β-D-thioglucoside; n-hexylβ-D-glucopyranoside; nonanoyl-N-methylglucamide; n-noylβ-D-glucopyranoside; octanoyl-N-methylglucamide;n-octyl-β-D-glucopyranoside; octyl β-D-thioglucopyranoside; and thelike.

Most of these surface stabilizers are known pharmaceutical excipientsand are described in detail in the Handbook of PharmaceuticalExcipients, published jointly by the American Pharmaceutical Associationand The Pharmaceutical Society of Great Britain (The PharmaceuticalPress, 2000), specifically incorporated by reference. The surfacestabilizers are commercially available and/or can be prepared bytechniques known in the art.

4. Nanoparticulate Drug/Copolymer Particle Size

Preferably, the compositions of the invention contain nanoparticleswhich have an effective average particle size of less than about 2000 nm(i.e., 2 microns), more preferably less than about 1500 nm, less thanabout 1000 nm, less than about 800 nm, less than about 600 nm, less thanabout 400 nm, less than about 300 nm, less than about 250 nm, less thanabout 100 nm, or less than about 50 nm, as measured by light-scatteringmethods, microscopy, or other appropriate methods. By “an effectiveaverage particle size of less than about 2000 nm” it is meant that atleast 50% of the drug particles have a particle size of less than about2000 nm when measured by light scattering techniques. Preferably, atleast 70% of the drug particles have a particle size of less than about2000 nm, more preferably at least 90% of the drug particles have aparticle size of less than about 2000 nm, and even more preferably atleast about 95% of the particles have a particle size of less than about2000 nm.

5. Concentration of Nanoparticulate Drug and Stabilizer

The relative amount of drug and one or more surface stabilizers can varywidely. The optimal amount of the surface stabilizers can depend, forexample, upon the particular active agent selected, the hydrophiliclipophilic balance (HLB), melting point, and water solubility of thecopolymer, and the surface tension of water solutions of the stabilizer,etc.

The concentration of the one or more surface stabilizers can vary fromabout 0.01 to about 90%, from about 1 to about 75%, from about 10 toabout 60%, and from about 10 to about 55% by weight based on the totalcombined weight of the drug substance and surface stabilizer, notincluding other excipients.

The concentration of the drug can vary from about 99.9% to about 0.1%,from about 80% to about 5.0%, or from about 50% to about 10%, by weightbased on the total combined weight of the drug substance and surfacestabilizer, not including other excipients.

B. Methods of Making Nanoparticulate Formulations

The nanoparticulate drug compositions can be made using, for example,milling or precipitation techniques. Exemplary methods of makingnanoparticulate compositions are described in the '684 patent. Methodsof making nanoparticulate compositions are also described in U.S. Pat.No. 5,518,187, for “Method of Grinding Pharmaceutical Substances;” U.S.Pat. No. 5,718,388, for “Continuous Method of Grinding PharmaceuticalSubstances;” U.S. Pat. No. 5,862,999, for “Method of GrindingPharmaceutical Substances;” U.S. Pat. No. 5,665,331, for“Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents withCrystal Growth Modifiers;” U.S. Pat. No. 5,662,883, for“Co-Microprecipitation of Nanoparticulate Pharmaceutical Agents withCrystal Growth Modifiers;” U.S. Pat. No. 5,560,932, for“Microprecipitation of Nanoparticulate Pharmaceutical Agents;” U.S. Pat.No. 5,543,133, for “Process of Preparing X-Ray Contrast CompositionsContaining Nanoparticles;” U.S. Pat. No. 5,534,270, for “Method ofPreparing Stable Drug Nanoparticles;” U.S. Pat. No. 5,510,118, for“Process of Preparing Therapeutic Compositions ContainingNanoparticles;” and U.S. Pat. No. 5,470,583, for “Method of PreparingNanoparticle Compositions Containing Charged Phospholipids to ReduceAggregation,” all of which are specifically incorporated by reference.

1. Milling to obtain Nanoparticulate Drug Dispersions

Milling of aqueous drug to obtain a nanoparticulate dispersion comprisesdispersing drug particles in a liquid dispersion medium in which thedrug is poorly soluble, followed by applying mechanical means in thepresence of grinding media to reduce the particle size of the drug tothe desired effective average particle size. The dispersion medium canbe, for example, water, safflower oil, ethanol, t-butanol, glycerin,polyethylene glycol (PEG), hexane, or glycol.

The particles can be reduced in size in the presence of at least onecopolymer of vinyl pyrrolidone and vinyl acetate surface stabilizer.Alternatively, the particles can be contacted with one or more surfacestabilizers after attrition. Other compounds, such as a diluent, can beadded to the drug/surface stabilizer composition during the sizereduction process. Dispersions can be manufactured continuously or in abatch mode. The resultant nanoparticulate drug dispersion can beutilized in solid or liquid dosage formulations.

2. Precipitation to Obtain Nanoparticulate Drug Compositions

Another method of forming the desired nanoparticulate composition is bymicroprecipitation. This is a method of preparing stable dispersions ofpoorly soluble drugs in the presence of one or more surface stabilizersand one or more colloid stability enhancing surface active agents freeof any trace toxic solvents or solubilized heavy metal impurities. Sucha method comprises, for example: (1) dissolving the poorly soluble drugin a suitable solvent; (2) adding the formulation from step (1) to asolution comprising at least one copolymer surface stabilizer to form aclear solution; and (3) precipitating the formulation from step (2)using an appropriate non-solvent. The method can be followed by removalof any formed salt, if present, by dialysis or diafiltration andconcentration of the dispersion by conventional means. The resultantnanoparticulate drug dispersion can be utilized in solid or liquiddosage formulations.

C. Methods of Using Nanoparticulate Drug Formulations Comprising One orMore Surface Stabilizers

The nanoparticulate compositions of the present invention can beadministered to humans and animals via any conventional means, includingbut not limited to orally, rectally, parenterally (intravenous,intramuscular, or subcutaneous), intracisternally, pulmonary,intravaginally, intraperitoneally, locally (powders, ointments ordrops), or as a buccal or nasal spray.

Compositions suitable for parenteral injection may comprisephysiologically acceptable sterile aqueous or nonaqueous solutions,dispersions, suspensions or emulsions and sterile powders forreconstitution into sterile injectable solutions or dispersions.Examples of suitable aqueous and nonaqueous carriers, diluents,solvents, or vehicles including water, ethanol, polyols(propyleneglycol, polyethylene-glycol, glycerol, and the like), suitablemixtures thereof, vegetable oils (such as olive oil) and injectableorganic esters such as ethyl oleate. Proper fluidity can be maintained,for example, by the use of a coating such as lecithin, by themaintenance of the required particle size in the case of dispersions,and by the use of surfactants.

The nanoparticulate compositions may also contain adjuvants such aspreserving, wetting, emulsifying, and dispensing agents. Prevention ofthe growth of microorganisms can be ensured by various antibacterial andantifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid,and the like. It may also be desirable to include isotonic agents, suchas sugars, sodium chloride, and the like. Prolonged absorption of theinjectable pharmaceutical form can be brought about by the use of agentsdelaying absorption, such as aluminum monostearate and gelatin.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, the activecompound is admixed with at least one of the following: (a) one or moreinert excipients (or carrier), such as sodium citrate or dicalciumphosphate; (b) fillers or extenders, such as starches, lactose, sucrose,glucose, mannitol, and silicic acid; (c) binders, such ascarboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone,sucrose and acacia; (d) humectants, such as glycerol; (e) disintegratingagents, such as agar-agar, calcium carbonate, potato or tapioca starch,alginic acid, certain complex silicates, and sodium carbonate; (f)solution retarders, such as paraffin; (g) absorption accelerators, suchas quaternary ammonium compounds; (h) wetting agents, such as cetylalcohol and glycerol monostearate; (i) adsorbents, such as kaolin andbentonite; and (j) lubricants, such as talc, calcium stearate, magnesiumstearate, solid polyethylene glycols, sodium lauryl sulfate, or mixturesthereof. For capsules, tablets, and pills, the dosage forms may alsocomprise buffering agents.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups, and elixirs. Inaddition to the active compounds, the liquid dosage forms may compriseinert diluents commonly used in the art, such as water or othersolvents, solubilizing agents, and emulsifiers. Exemplary emulsifiersare ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate,benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol,dimethylformamide, oils, such as cottonseed oil, groundnut oil, corngerm oil, olive oil, castor oil, and sesame oil, glycerol,tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters ofsorbitan, or mixtures of these substances, and the like.

Besides such inert diluents, the composition can also include adjuvants,such as wetting agents, emulsifying and suspending agents, sweetening,flavoring, and perfuming agents.

Actual dosage levels of active ingredients in the nanoparticulatecompositions of the invention may be varied to obtain an amount ofactive ingredient that is effective to obtain a desired therapeuticresponse for a particular composition and method of administration. Theselected dosage level therefore depends upon the desired therapeuticeffect, the route of administration, the potency of the administereddrug, the desired duration of treatment, and other factors.

The total daily dose of the compounds of this invention administered toa host in single or divided dose may be in amounts of, for example, fromabout 1 nanomol to about 50 micromoles per kilogram of body weight.Dosage unit compositions may contain such amounts of such submultiplesthereof as may be used to make up the daily dose. It will be understood,however, that the specific dose level for any particular patient willdepend upon a variety of factors including the body weight, generalhealth, sex, diet, time and route of administration, potency of theadministered drug, rates of absorption and excretion, combination withother drugs and the severity of the particular disease being treated.

The following examples are given to illustrate the present invention. Itshould be understood, however, that the invention is not to be limitedto the specific conditions or details described in these examples.Throughout the specification, any and all references to a publiclyavailable document, including a U.S. patent, are specificallyincorporated by reference.

EXAMPLE 1

The purpose of this example was to prepare a nanoparticulate dispersionof a naproxen composition comprising a copolymer of vinyl pyrrolidoneand vinyl acetate. Naproxen is a non-steroidal anti-inflammatory drug(NSAID) used in the treatment of rheumatoid conditions.

5% (w/w) of naproxen and 1% Plasdone® S-630 (60% vinyl pyrrolidone, 40%vinyl acetate) (ISP Technologies, Inc.) was milled using a Dyno® Mill(Type: KDL; Mfg.: Willy A Bachofen A G, Basel Switzerland) equipped witha 150 cc batch chamber using a 500 μm milling media (PolyMill® 500; bowChemical) for 2 hrs at ca. 10° C.

Following milling, the nanoparticulate naproxen dispersion had a meanparticle size of 96 nm, with 90% of the particles having a size of lessthan 141 nm.

EXAMPLE 2

The purpose of this example was to prepare a nanoparticulate dispersionof a nifedipine composition comprising a copolymer of vinyl pyrrolidoneand vinyl acetate. Nifedipine is a poorly water-soluble calcium channelblocking agent. The drug affects the movement of calcium into heart andblood vessel cells, and causes a relaxing effect of the muscles to allowan increased amount of blood flow into the heart. Nifedipine is usefulin treating angina pectoris (chest pain), and to help reduce bloodpressure (antihypertensive).

An aqueous solution of 1% Plasdone® S-630 (60% vinyl pyrrolidone and 40%vinyl acetate) (ISP Technologies, Inc.) and 0.05% sodium lauryl sulfate(SLS) (Spectrum) was prepared by dissolving 0.85 g of polymer and 4.59 gof a 1% SLS solution in 75.66 g of deionized water. The stabilizersolution was mixed with 4.25 g of nifedipine (5% w/w) and charged intothe chamber of a DYNO®-Mill Type KDL media mill (Willy Bachofen A G,Basel, Switzerland) along with 500 micron polymeric media (PolyMill®500; Dow Chemical). The mill was operated for 2 hours and yielded astable colloidal dispersion of drug substance having a mean particlesize of 132 nm, with 90% of the particles having a size of less than 193nm.

EXAMPLE 3

The purpose of this example was to prepare a nanoparticulate dispersionof a ketoprofen composition comprising a copolymer of vinyl pyrrolidoneand vinyl acetate. Ketoprofen is a nonsteroidal anti-inflammatory drug(NSAID) effective in treating fever, pain, and inflammation in the body.

An aqueous solution of 1% Plasdone® S-630 (60% vinyl pyrrolidone and 40%vinyl acetate) (ISP Technologies, Inc.) and 0.05% sodium lauryl sulfate(SLS) (Spectrum) was prepared by dissolving 0.85 g of polymer and 4.26 gof a 1% SLS solution in 75.71 g of deionized water. The stabilizersolution was mixed with 4.25 g of ketoprofen (Wyckoff; 5% w/w) andcharged into the chamber of a DYNO®-Mill Type KDL media mill (WillyBachofen A G, Basel, Switzerland) along with 500 micron polymeric media(PolyMill® 500; Dow Chemical). The mill was operated for 1 hour andyielded a stable colloidal dispersion of drug substance having a meanparticle size of 256 nm, with 90% of the particles having a size of lessthan 355 nm.

EXAMPLE 4

The purpose of this example was to prepare a nanoparticulate dispersionof a triamcinolone acetonide composition comprising a copolymer of vinylpyrrolidone and vinyl acetate. Triamcinolone acetonide is acorticosteroid used as an antiallergic agent.

An aqueous solution of 1% Plasdone® S-630 (60% vinyl pyrrolidone and 40%vinyl acetate) (ISP Technologies, Inc.) and 0.05% sodium lauryl sulfate(SLS) (Spectrum) was prepared by dissolving 0.85 g of polymer and 4.30 gof a 1% SLS solution in 76.10 g of deionized water. The stabilizersolution was mixed with 4.26 g of triamcinolone acetonide (5% w/w) andcharged into the chamber of a DYNO®-Mill Type KDL media mill (WillyBachofen A G, Basel, Switzerland) along with 500 micron polymeric media(PolyMill® 500; Dow Chemical). The mill was operated for 2 hours andyielded a colloidal dispersion of drug substance having a mean particlesize of 121 nm, with 90% of the particles having a size of less than 194nm.

EXAMPLE 5

The purpose of this example was to prepare a nanoparticulate dispersionof a nanoparticulate diagnostic imaging agent, benzoic acid,3,5-bis(acetylamino) 2,4,6-triodo, 4-(ethyl-3-ethoxy-2-butenoate) ester(WIN 68209) composition comprising a copolymer of vinyl pyrrolidone andvinyl acetate.

An aqueous solution of 1% of a copolymer of 80% vinyl pyrrolidone and20% vinyl acetate (Polysciences Inc., Warrington, Pa.) was prepared bydissolving 0.85 g of polymer in 79.91 g of deionized water. Thestabilizer solution was mixed with 4.26 g of WIN 68209 (5% drug) andcharged into the chamber of a DYNO®-Mill Type KDL media mill (WillyBachofen A G, Basel, Switzerland) along with 500 micron polymeric media(PolyMill 500; Dow Chemical). The mill was operated for 1 hour andyielded a stable colloidal dispersion of WIN 68209 having a meanparticle size of 242 nm, with 90% of the particles having a size of lessthan 347 nm.

EXAMPLE 6

The purpose of this example was to prepare a nanoparticulate dispersionof a nanoparticulate diagnostic imaging agent, WIN 68209, compositioncomprising a copolymer of vinyl pyrrolidone and vinyl acetate.

An aqueous solution of 1% of a copolymer of 80% vinyl pyrrolidone and20% vinyl acetate (Polysciences Inc., Warrington, Pa.) and 1% SLS wasprepared by dissolving 0.85 g of polymer and 4.25 g of a 1% SLS solutionin 75.67 g of deionized water. The stabilizer solution was mixed with4.26 g of WIN 68209 (5% drug) and charged into the chamber of aDYNO®-Mill Type KDL media mill (Willy Bachofen A G, Basel, Switzerland)along with 500 micron polymeric media (PolyMill 500; Dow Chemical). Themill was operated for 1 hour and yielded a stable colloidal dispersionof WIN 68209 having a mean particle size of 188 nm, with 90% of theparticles having a size of less than 308 nm.

EXAMPLE 7

The purpose of this example was to prepare a nanoparticulate dispersionof a nanoparticulate diagnostic imaging agent, WIN 68209, compositioncomprising a copolymer of vinyl pyrrolidone and vinyl acetate.

An aqueous solution of 1% of a copolymer of 50% vinyl pyrrolidone and50% vinyl acetate (Polysciences Inc., Warrington, Pa.) and 0.05% SLS(Spectrum) was prepared by dissolving 0.85 g of polymer and 0.043 g ofSLS in 79.86 g of deionized water. The stabilizer solution was mixedwith 4.25 g of WIN 68209 (5% drug) and charged into the chamber of aDYNO®-Mill Type KDL media mill (Willy Bachofen A G, Basel, Switzerland)along with 500 micron polymeric media (PolyMill 500; Dow Chemical). Themill was operated for 2 hours and yielded a stable colloidal dispersionof WIN 68209 having a mean particle size of 96 nm, with 90% of theparticles having a size of less than 143 nm.

It will be apparent to those skilled in the art that variousmodifications and variations can be made in the methods and compositionsof the present invention without departing from the spirit or scope ofthe invention. Thus, it is intended that the present invention cover themodifications and variations of this invention provided they come withinthe scope of the appended claims and their equivalents.

1. A stable nanoparticulate drug composition comprising: (a) a drughaving an effective average particle size of less than about 2000 nm,wherein the drug has a solubility in at least one liquid dispersionmedium of less than about 10 mg/mL; and (b) at least one copolymer ofvinyl pyrrolidone and vinyl acetate adsorbed on the surface thereof as asurface stabilizer.
 2. The composition of claim 1, wherein the copolymerof vinyl pyrrolidone and vinyl acetate has from about 40% up to about99.9% vinyl pyrrolidone and about 0.1% up to about 60% vinyl acetate. 3.The composition of claim 2, wherein the copolymer of vinyl pyrrolidoneand vinyl acetate has from about 50% up to about 99.9% vinyl pyrrolidoneand about 0.1% up to about 50% vinyl acetate.
 4. The composition ofclaim 2, wherein the copolymer of vinyl pyrrolidone and vinyl acetatehas about 60% vinyl pyrrolidone and about 40% vinyl acetate.
 5. Thecomposition of claim 2, wherein the copolymer of vinyl pyrrolidone andvinyl acetate has about 80% vinyl pyrrolidone and about 20% vinylacetate.
 6. The composition of claim 1, wherein the drug is present inan amount selected from the group consisting of from about 99.9% toabout 0.1%, from about 80% to about 5.0%, and from about 50% to about10%, by weight based on the total combined weight of the drug substanceand surface stabilizer, not including other excipients.
 7. Thecomposition of claim 1, wherein at least one copolymer of vinylpyrrolidone and vinyl acetate is present in an amount selected from thegroup consisting of from about 0.1 to about 90%, from about 1 to about75%, from about 10 to about 60%, and from about 10 to about 55%, byweight based on the total combined weight of the drug substance andsurface stabilizer, not including other excipients.
 8. The compositionof claim 1, wherein the drug is selected from the group consisting of acrystalline phase drug and an amorphous phase drug.
 9. The compositionof claim 1, further comprising at least one surface stabilizer which isnot a copolymer of vinyl pyrrolidone and vinyl acetate.
 10. Thecomposition of claim 1, comprising two or more copolymers of vinylpyrrolidone and vinyl acetate.
 11. The composition of claim 1, whereinthe effective average particle size of the drug present in thenanoparticulate composition is less than about 1500 nm.
 12. Thecomposition of claim 11, wherein the effective average particle size ofthe drug present in the nanoparticulate composition is less than about1000 nm.
 13. The composition of claim 12, wherein the effective averageparticle size of the drug present in the nanoparticulate composition isless than about 800 nm.
 14. The composition of claim 13, wherein theeffective average particle size of the drug present in thenanoparticulate composition is less than about 600 nm.
 15. Thecomposition of claim 14, wherein the effective average particle size ofthe drug present in the nanoparticulate composition is less than about400 nm.
 16. The composition of claim 15, wherein the effective averageparticle size of the drug present in the nanoparticulate composition isless than about 300 nm.
 17. The composition of claim 16, wherein theeffective average particle size of the drug present in thenanoparticulate composition is less than about 200 nm.
 18. Thecomposition of claim 17, wherein the effective average particle size ofthe drug present in the nanoparticulate composition is less than about100 nm.
 19. The composition of claim 18, wherein the effective averageparticle size of the drug present in the nanoparticulate composition isless than about 50 nm.
 20. A method of treating a patient in need with astable nanoparticulate drug composition comprising an organic drug,wherein said method comprises: (a) administering to a mammal in need atherapeutically effective amount of the nanoparticulate drug compositioncomprising: (1) an organic drug having an effective average particlesize of less than about 2000 nm wherein the drug has a solubility in atleast one liquid dispersion medium of less than about 10 mg/mL; and (2)at least one copolymer of vinyl pyrrolidone and vinyl acetate as asurface stabilizer adsorbed on the surface of the drug.
 21. The methodof claim 20, wherein the copolymer of vinyl pyrrolidone and vinylacetate has from about 40% up to about 99.9% vinyl pyrrolidone and about0.1% up to about 60% vinyl acetate.
 22. The method of claim 20, whereinthe drug is present in an amount selected from the group consisting offrom about 99.9% to about 0.1%, from about 80% to about 5.0%, and fromabout 50% to about 10%, by weight based on the total combined weight ofthe drug substance and surface stabilizer, not including otherexcipients.
 23. The method of claim 20, wherein the at least onecopolymer of vinyl pyrrolidone and vinyl acetate is present in an amountselected from the group consisting of from about 0.1 to about 90%, fromabout 1 to about 75%, from about 10 to about 60%, and from about 10 toabout 55%, by weight based on the total combined weight of the drugsubstance and surface stabilizer, not including other excipients. 24.The method of claim 20, wherein the drug is selected from the groupconsisting of a crystalline phase drug and an amorphous phase drug. 25.The method of claim 20, wherein the effective average particle size ofthe drug present in the nanoparticulate composition is selected from thegroup consisting of less than about 1500 nm, less than about 1000 nm,less than about 800 nm, less than about 600 nm, less than about 400 nm,less than about 300 nm, less than about 200 nm, less than about 100 nm,and less than about 50 nm.
 26. The composition of claim 1, wherein thedrug has a solubility in at least one liquid dispersion medium of lessthan about 1 mg/mL.
 27. The composition of claim 1, wherein the liquiddispersion medium is selected from the group consisting of water,safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG),hexane, and glycol.
 28. The composition of claim 1, wherein the drug isselected from the group consisting of proteins, peptides, nucleotides,anti-obesity drugs, nutraceuticals, corticosteroids, elastaseinhibitors, analgesics, anti-fungals, oncology therapies, anti-emetics,analgesics, cardiovascular agents, anti-inflammatory agents,anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants,antidepressants, antidiabetic agents, antiepileptics, antihistamines,antihypertensive agents, antimuscarinic agents, antimycobacterialagents, antineoplastic agents, immunosuppressants, antithyroid agents,antiviral agents, anxiolytic sedatives, astringents, beta-adrenoceptorblocking agents, blood products, blood substitutes, cardiac inotropicagents, contrast media, corticosteroids, cough suppressants, diagnosticagents, diagnostic imaging agents, diuretics, dopaminergics,haemostatics, immunological agents, lipid regulating agents, musclerelaxants, parasympathomimetics, parathyroid calcitonin, parathyroidbiphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones,anti-allergic agents, stimulants, anoretics, sympathomimetics, thyroidagents, vasodilators, and xanthines.
 29. The composition of claim 1,wherein the drug is selected from the group consisting of naproxen,nifedipine, ketoprofen, triamcinolone acetonide, and WIN
 68209. 30. Thecomposition of claim 9, wherein the at least one surface stabilizerwhich is not a copolymer of vinyl pyrrolidone and vinyl acetate isselected from the group consisting of cetyl pyridinium chloride,gelatin, casein, lecithin, dextran, glycerol, gum acacia, cholesterol,tragacanth, stearic acid, benzalkonium chloride, calcium stearate,glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifyingwax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylenecastor oil derivatives, polyoxyethylene sorbitan fatty acid esters,polyethylene glycols, dodecyl trimethyl ammonium bromide,polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodiumdodecylsulfate, carboxymethylcellulose calcium, hydroxypropylcelluloses, hydroxypropyl methylcellulose, carboxymethylcellulosesodium, methylcellulose, hydroxyethylcellulose,hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose,magnesium aluminum silicate, triethanolamine, polyvinyl alcohol,polyvinylpyrrolidone, tyloxapol, poloxamers, poloxamines, a chargedphospholipid, dioctylsulfosuccinate, Tetronic 1508®, dialkylesters ofsodium sulfosuccinic acid, sodium lauryl sulfate, an alkyl arylpolyether sulfonate, a mixture of sucrose stearate and sucrosedistearate, p-isononylphenoxypoly-(glycidol), Crodestas SL-40®,decanoyl-N-methylglucamide, n-decyl β-D-glucopyranoside, n-decylβ-D-maltopyranoside, n-dodecyl β-D-glucopyranoside, n-dodecylβ-D-maltoside, heptanoyl-N-methylglucamide,n-heptyl-β-D-glucopyranoside, n-heptyl β-D-thioglucoside, n-hexylβ-D-glucopyranoside, nonanoyl-N-methylglucamide, n-noylβ-D-glucopyranoside, octanoyl-N-methylglucamide,n-octyl-β-D-glucopyranoside, and octyl β-D-thioglucopyranoside.
 31. Thecomposition of claim 9, wherein the at least one surface stabilizerwhich is not a copolymer of vinyl pyrrolidone and vinyl acetate isselected from the group consisting of sodium lauryl sulfate anddioctylsulfosuccinate.
 32. The method of claim 20, wherein the drug hasa solubility in at least one liquid dispersion medium of less than about1 mg/mL.
 33. The method of claim 20, wherein the liquid dispersionmedium is selected from the group consisting of water, safflower oil,ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, andglycol.
 34. The method of claim 20, wherein the drug is selected fromthe group consisting of proteins, peptides, nucleotides, anti-obesitydrugs, nutraceuticals, corticosteroids, elastase inhibitors, analgesics,anti-fungals, oncology therapies, anti-emetics, analgesics,cardiovascular agents, anti-inflammatory agents, anthelmintics,anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants,antidiabetic agents, antiepileptics, antihistamines, antihypertensiveagents, antimuscarinic agents, antimycobacterial agents, antineoplasticagents, immunosuppressants, antithyroid agents, antiviral agents,anxiolytic sedatives, astringents, beta-adrenoceptor blocking agents,blood products, blood substitutes, cardiac inotropic agents, contrastmedia, corticosteroids, cough suppressants, diagnostic agents,diagnostic imaging agents, diuretics, dopaminergics, haemostatics,immunological agents, lipid regulating agents, muscle relaxants,parasympathomimetics, parathyroid calcitonin, parathyroidbiphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones,anti-allergic agents, stimulants, anoretics, sympathomimetics, thyroidagents, vasodilators, and xanthines.
 35. The method of claim 20, whereinthe drug is selected from the group consisting of naproxen, nifedipine,ketoprofen, triamcinolone acetonide, and WIN
 68209. 36. The method ofclaim 20, wherein the composition further comprises at least one surfacestabilizer which is not a copolymer of vinyl pyrrolidone and vinylacetate.
 37. The method of claim 36, wherein the at least one surfacestabilizer which is not a copolymer of vinyl pyrrolidone and vinylacetate is selected from the group consisting of cetyl pyridiniumchloride, gelatin, casein, lecithin, dextran, glycerol, gum acacia,cholesterol, tragacanth, stearic acid, benzalkonium chloride, calciumstearate, glycerol monostearate, cetostearyl alcohol, cetomacrogolemulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers,polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fattyacid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide,polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodiumdodecylsulfate, carboxymethylcellulose calcium, hydroxypropylcelluloses, hydroxypropyl methylcellulose, carboxymethylcellulosesodium, methylcellulose, hydroxyethylcellulose,hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose,magnesium aluminum silicate, triethanolamine, polyvinyl alcohol,polyvinylpyrrolidone, tyloxapol, poloxamers, poloxamines, a chargedphospholipid, dioctylsulfosuccinate, Tetronic 1508®, dialkylesters ofsodium sulfosuccinic acid, sodium lauryl sulfate, an alkyl arylpolyether sulfonate, a mixture of sucrose stearate and sucrosedistearate, p-isononylphenoxypoly-(glycidol), Crodestas SL-40®,decanoyl-N-methylglucamide, n-decyl β-D-glucopyranoside, n-decylβ-D-maltopyranoside, n-dodecyl β-D-glucopyranoside, n-dodecylβ-D-maltoside, heptanoyl-N-methylglucamide,n-heptyl-β-D-glucopyranoside, n-heptyl β-D-thioglucoside, n-hexylβ-D-glucopyranoside, nonanoyl-N-methylglucamide, n-noylβ-D-glucopyranoside, octanoyl-N-methylglucamide,n-octyl-β-D-glucopyranoside, and octyl β-D-thioglucopyranoside.
 38. Themethod of claim 36, wherein the at least one surface stabilizer which isnot a copolymer of vinyl pyrrolidone and vinyl acetate is selected fromthe group consisting of sodium lauryl sulfate and dioctylsulfosuccinate.